These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 24793219)

  • 21. A review of gliptins in 2011.
    Scheen AJ
    Expert Opin Pharmacother; 2012 Jan; 13(1):81-99. PubMed ID: 22149369
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, or vildagliptin.
    Tatosian DA; Guo Y; Schaeffer AK; Gaibu N; Popa S; Stoch A; Langdon RB; Kauh EA
    Diabetes Ther; 2013 Dec; 4(2):431-42. PubMed ID: 24163113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gliptins (dipeptidyl peptidase-4 inhibitors) and risk of acute pancreatitis.
    Scheen A
    Expert Opin Drug Saf; 2013 Jul; 12(4):545-57. PubMed ID: 23621381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis.
    Gooßen K; Gräber S
    Diabetes Obes Metab; 2012 Dec; 14(12):1061-72. PubMed ID: 22519906
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DPP-4 inhibitors: focus on safety.
    Tella SH; Rendell MS
    Expert Opin Drug Saf; 2015 Jan; 14(1):127-40. PubMed ID: 25488788
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacology of dipeptidyl peptidase-4 inhibitors: similarities and differences.
    Baetta R; Corsini A
    Drugs; 2011 Jul; 71(11):1441-67. PubMed ID: 21812507
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dipeptidyl peptidase-4 inhibitors in triple oral therapy regimens in patients with type 2 diabetes mellitus.
    Barnett AH; Charbonnel B; Moses RG; Kalra S
    Curr Med Res Opin; 2015; 31(10):1919-31. PubMed ID: 26361231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DPP-4 Inhibition and the Path to Clinical Proof.
    Ahrén B
    Front Endocrinol (Lausanne); 2019; 10():376. PubMed ID: 31275243
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tolerability of dipeptidyl peptidase-4 inhibitors: a review.
    Richard KR; Shelburne JS; Kirk JK
    Clin Ther; 2011 Nov; 33(11):1609-29. PubMed ID: 22071236
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes.
    Scheen AJ
    Postgrad Med; 2013 May; 125(3):7-20. PubMed ID: 23748503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An update in incretin-based therapy: a focus on dipeptidyl peptidase--4 inhibitors.
    Irons BK; Weis JM; Stapleton MR; Edwards KL
    Curr Diabetes Rev; 2012 May; 8(3):169-82. PubMed ID: 22429011
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linagliptin as add-on therapy for type 2 diabetes - an overview.
    Brown DX; Choudhury M; Evans M
    Drugs Today (Barc); 2012 Oct; 48(10):645-54. PubMed ID: 23110260
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact on decision making framework for medicine purchasing in Chinese public hospital decision-making: determining the value of five dipeptidyl peptidase 4 (DPP-4) inhibitors.
    Bao Y; Gao B; Meng M; Ge B; Yang Y; Ding C; Shi B; Tian L
    BMC Health Serv Res; 2021 Aug; 21(1):807. PubMed ID: 34384428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alogliptin for the treatment of type 2 diabetes.
    White JR
    Drugs Today (Barc); 2011 Feb; 47(2):99-107. PubMed ID: 21431099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences in baseline characteristics between type 2 diabetes mellitus patients treated with dipeptidyl peptidase-4 inhibitors in randomized controlled trials and those receiving the same treatment in real-world settings
.
    Kostev K; Schokker E; Jacob L
    Int J Clin Pharmacol Ther; 2018 Sep; 56(9):411-416. PubMed ID: 30049306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of Dipeptidyl Peptidase-4 Inhibitors on Hyperglycemia and Blood Cyclosporine Levels in Renal Transplant Patients with Diabetes: A Pilot Study.
    Bae J; Lee MJ; Choe EY; Jung CH; Wang HJ; Kim MS; Kim YS; Park JY; Kang ES
    Endocrinol Metab (Seoul); 2016 Mar; 31(1):161-7. PubMed ID: 26754588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacology, efficacy, and safety of linagliptin for the treatment of type 2 diabetes mellitus.
    Neumiller JJ
    Ann Pharmacother; 2012 Mar; 46(3):358-67. PubMed ID: 22318932
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical trial simulation methods for estimating the impact of DPP-4 inhibitors on cardiovascular disease.
    Schuetz CA; Ong SH; Blüher M
    Clinicoecon Outcomes Res; 2015; 7():313-23. PubMed ID: 26089691
    [TBL] [Abstract][Full Text] [Related]  

  • 39. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials.
    Yang W; Cai X; Han X; Ji L
    Diabetes Metab Res Rev; 2016 May; 32(4):391-404. PubMed ID: 26417956
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.